Advances in Pharmaceutical Analysis 2021
The RSC Molecular Spectroscopy Group
Duncan Bryant Award Meeting:
“Advances in Pharmaceutical Analysis”
to be held on:
Thursday 23rd September 2021
online GoTo Webinar, 9:30am - 12:15pm
The RSC Molecular Spectroscopy Group are delighted to announce a special edition of our successful Online Seminar Series, which will be the inaugural Duncan Bryant Award Meeting, to be held on Thursday 23rd September 2021.
The MSG have been presenting the Duncan Bryant Award, in honour of our former chairman, for over 13 years and for the first time we are dedicating a meeting to this award, based on the theme of Advances in Pharmaceutical Analysis at which the most recent recipient, Deeba Zahoor (Sheffield Hallam), will receive here prize and give the closing lecture.
FREE registration is now open for this cross analytical discipline meeting, which will focus on recent advances in pharmaceutical applications and research. Presentations will include a mix of various different analytical skill areas covering a wide breadth of pharmaceutical research, from early discovery through to drug product formulation and release testing, including advances in the latest techniques of MS, NMR, FT-IR, THz and Raman spectroscopies. The virtual 1/2 day meeting is a GoTo webinar format, with both invited and selected talks from submitted abstract submissions – the full program is listed below.
PROGRAMME
09:30 - 09:45 Introduction and welcome
09:45 - 10:15 The evolving world of pharmaceutical development – where is analytical innovation required?
Marcel de Matas, Founder & Director, Seda Pharmaceutical Development Services
10:15 - 10:40 Mapping Structurally Significant Areas of G-CSF during Thermal Degradation with NMR
Mark-Adam Kellerman, Research student, UCL
10:40 - 11:05 Evaluation of atmospheric solid analysis probe mass spectrometry (ASAP) on a compact mass spectrometer in a process chemistry environment
Stephen Holman, AstraZeneca
11:05 - 11:15 Break
11:15 - 11:40 Determination of the solubility of a crystalline active pharmaceutical ingredient in a polymer during hot melt extrusion using terahertz - Raman spectroscopy
Pattavet Vivattanaseth, University of Strathclyde & University of Phayao
11:40 - 12:10 The Duncan Bryant Award lecture
Investigation of Within-Tablet Dynamics for Extended Release of a Poorly Soluble Basic Drug from Hydrophilic Matrix Tablets Using ATR−FTIR Imaging
Deeba Zahoor, Sheffield Hallam University
12:10 - 12:15 Wrap up
12:15 Meeting close
REGISTRATION
To register for this meeting, please visit the RSC event registration page here
SPEAKER PROFILES
Deeba Zahoor: Sheffield Hallam University - Duncan Bryant Award winner 2020
Deeba graduated with a degree in Chemistry from Sheffield Hallam University (SHU) and following that, spent a number of years working in industry, including in the pharmaceutical and aerosol development sectors. Deeba returned to SHU in a technical role within the Materials and Engineering Research Institute, delivering consultancy and training researchers on various pieces of equipment which fall within my area of expertise, including FTIR, Raman, DSC and TGA. Deeba is also an Associate Lecturer, teaching undergraduate students in the Department of Engineering and Maths, with particular emphasis on teaching safety-related topics and materials characterisation. In September 2020, Deeba left her technical role at SHU and moved to the Department of Chemistry at University of Sheffield as the Departmental Safety Officer. However, she has retained her association with SHU as an Associate Lecturer and is currently finishing her part-time PhD on the subject of vibrational spectroscopy as a means of assessing the release of poorly-soluble drugs from hydrophilic matrices, supervised by Professor Chris Sammon, Peter Timmins (University of Huddersfield) and Jonathan Brown (BMS).
Stephen Holman: Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, UK.
Stephen is an associate principal scientist at AstraZeneca, leading mass spectrometry activities in late-stage chemistry. He was awarded a PhD from the University of Southampton in 2010 under the supervision of Professor John Langley, collaborating with Pfizer on the application of tandem mass spectrometry to small molecule drug metabolite structural elucidation. Stephen was a post-doc at the Universities of Manchester and Liverpool, working in the area of quantitative proteomics, before joining Waters as a senior applications chemist specialising in biopharmaceuticals. He then joined AZ in late 2018. Stephen has published 28 papers on the application of mass spectrometry, and is currently chair of the associate editorial board of Rapid Communications in Mass Spectrometry.
Mark-Adam Kellerman: Final year PhD student, Biochemical Engineering, University College London & NIBSC.
My research mainly consists of devising protein engineering approaches for rational mutagenesis. Methods I typically use to achieve this include molecular dynamics (MD), NMR and formulation with excipients. After completing my BSc in Medical Biochemistry and MSc in Infection and Immunology at the University of Leicester, I took an interest in biotherapeutic development. Under the supervision of Prof. Paul Dalby at UCL and Dr. Paul Matejtschuk and Dr. Tim Rudd at NIBSC, I have had great support and the necessary tools to address my research question.
Pattavet Vivattanaseth: PhD student, Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC), University of Strathclyde.
Pattavet is a PhD student in the Centre for Continuous Manufacturing and Advanced Crystallisation at the University of Strathclyde. His research is in improving drug solubility by generating solid dispersions using continuous manufacturing techniques such as hot-melt extrusion and confirming the results with process analytical technology such as in situ terahertz Raman spectroscopy. Pattavet completed a Bachelor's degree from the Faculty of Pharmacy, Chiang Mai University, Thailand and a Master's degree in Advanced Pharmaceutical Manufacturing from Strathclyde Institute of Pharmacy & Biomedical Sciences (SIPBs), University of Strathclyde, Glasgow. He joined CMAC in 2019 to carry out a PhD supervised by Dr Alison Nordon and Dr John Robertson.
Marcel de Matas: Seda Pharmaceutical Development Services.
Marcel de Matas is the cofounder and Director of Seda Pharmaceutical Development Services, which is focussed on helping biotechnology and drug delivery companies to progress new medicinal products and technologies into clinical development and towards commercialisation. In his current role he has worked with his business partners Paul Stott and Paul Dickinson to drive the growth of the business, which now has >20 permanent employees and >10 associates who work with Seda to support over 50 different biotech organisations. During his 24-year career, Marcel has held a range of management and senior scientific positions in industry and academia including leadership roles in Product Design and Innovation at AstraZeneca, where he was responsible for finding and implementing new science and technology in the Pharmaceutical Development group. Marcel has provided project leadership and led product development teams responsible for the delivery of drug projects from initial concept design through late stage development and regulatory submission in readiness for launch. This has included a focus on enabling technologies for drug delivery. He has also led teams at the drug discovery-development interface, assessing the level of chemistry manufacturing and control (CMC) technical risk and defining product design strategies in early development. Project experience has covered molecules across a range of disease and therapy areas with substantial experience in the oncology field.